


Chemical Science

rsc.li/chemical-science



ISSN 2041-6539

EDGE ARTICLE

Paul S. Donnelly *et al.*
Enzyme mediated incorporation of zirconium-89
or copper-64 into a fragment antibody for same day
imaging of epidermal growth factor receptor



Cite this: *Chem. Sci.*, 2021, **12**, 9004

All publication charges for this article have been paid for by the Royal Society of Chemistry

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor†

Stacey E. Rudd,^a Jessica K. Van Zuylenkom,^{id}^b Anna Raicevic,^c Lesley A. Pearce,^c Carleen Cullinane,^{bd} Charlotte C. Williams,^c Timothy E. Adams,^c Rodney J. Hicks^d and Paul S. Donnelly^{id, *a}

Identification of tumors which over-express Epidermal Growth Factor Receptor (EGFR) is important in selecting patients for anti-EGFR therapies. Enzymatic bioconjugation was used to introduce positron-emitting radionuclides (⁸⁹Zr, ⁶⁴Cu) into an anti-EGFR antibody fragment for Positron Emission Tomography (PET) imaging the same day as injection. A monovalent antibody fragment with high affinity for EGFR was engineered to include a sequence that is recognized by the transpeptidase sortase A. Two different metal chelators, one for ⁸⁹Zr^{IV} and one for ⁶⁴Cu^{II}, were modified with a N-terminal glycine to enable them to act as substrates in sortase A mediated bioconjugation to the antibody fragment. Both fragments provided high-quality PET images of EGFR positive tumors in a mouse model at 3 hours post-injection, a significant advantage when compared to radiolabeled full antibodies that require several days between injection of the tracer and imaging. The use of enzymatic bioconjugation gives reproducible homogeneous products with the metal complexes selectively installed on the C-terminus of the antibody potentially simplifying regulatory approval.

Received 11th March 2021
Accepted 23rd May 2021

DOI: 10.1039/d1sc01422f
rsc.li/chemical-science

Introduction

Human epidermal growth factor receptor (EGFR) (also known as erbB1) is a 170 kDa type I transmembrane protein tyrosine kinase involved in signal transduction, cell growth and division.¹ A wide range of malignant tumors over-express EGFR including bladder, lung, breast and colorectal cancers, where the overexpression is associated with resistance to chemotherapy. Therapies that target EGFR, such as the antibody cetuximab and tyrosine kinase inhibitors such as gefitinib, can be remarkably effective but identification of patients most likely to respond to these treatments is essential.^{2–4} Unfortunately, biopsies for EGFR expression do not always reflect the EGFR burden of heterogenous tumors and do not always predict a likely response to anti-EGFR therapy.^{5,6} An alternative approach to identify EGFR positive tumors is to perform diagnostic Positron Emission Tomography (PET) imaging with

radiolabeled antibodies. Most research on PET imaging of EGFR has focused on the use of radiolabeled anti-EGFR full IgG antibodies.^{7,8} Such antibody-based probes take several days to clear from the blood and accumulate in the tumor due to their large molecular weight (~150 kDa) as well as interactions between their Fc (fragment crystallisable) region and Fc-gamma receptors on a myriad of cell types. It is therefore necessary to image the patient several days after injection of the tracer. The several days required between injection and imaging is not always practical in a clinical setting. Radiolabeled smaller engineered antibody fragments such as a Fab (fragment antigen-binding) (~55 kDa) and F(ab')₂ fragments (~110 kDa) retain the selectivity to the antigen, but clear from the blood and accumulate in tumors more rapidly as they lack the Fc region.^{9,10} This earlier time point imaging is often compromised by lower tumor uptake and higher kidney uptake when compared to tracers that use full IgG antibodies.¹¹ Nonetheless, the potential of imaging on the same day as injection is an important consideration when developing a tracer for routine clinical use.

In this work, we aimed to produce conjugates that enable same-day imaging of tumor EGFR expression using a recombinant Fab of an anti-EGFR murine monoclonal antibody, Fab528 (~52 kDa)¹² that was engineered for site-specific radiolabeling with either of the positron emitting radionuclides zirconium-89 ($t_{1/2} = 79$ h, $\beta_{\text{mean}}^+ = 0.396$ MeV) or copper-64 ($t_{1/2} = 12.7$ h, $\beta_{\text{mean}}^+ = 0.278$ MeV). Labeling of Fabs with metal ions requires the incorporation of specifically designed metal chelators. A

^aSchool of Chemistry and Bio21 Molecular Science, Biotechnology Institute University of Melbourne, Parkville, Victoria 3010, Australia. E-mail: pauld@unimelb.edu.au

^bResearch Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia

^cCSIRO Manufacturing, Parkville, Victoria 3052, Australia

^dSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia

† Electronic supplementary information (ESI) available: Chemical synthesis of H₃L¹ and L², supplementary Fig. 1–6. See DOI: 10.1039/d1sc01422f






Fig. 1 Schematic representation of the enzyme-mediated bioconjugation of a chelator to a Fab using SrtA at the C-terminal recognition sequence (LPETG).

conventional approach to attach chelators to Fabs is to use metal-binding chelators bearing *N*-hydroxysuccinimidyl esters that react with the amine functional group of lysine residues on the Fab. The multiple lysine residues present on Fabs leads to heterogeneous products with various numbers of chelators attached. Furthermore, modifications involving residues close to the antigen binding site can compromise biological activity by blocking interaction with the receptor. In this context it is preferable to achieve controlled site-specific conjugation. Several methodologies for site-specific incorporation of chelators have been developed including the incorporation of unnatural amino acids with biorthogonal functional groups for pre-targeting applications,^{8,13} or additional cysteine residues for subsequent maleimide conjugation chemistry.^{14,15} Enzymatic bioconjugations with enzymes such as transglutaminase,^{16–18} engineered galactosyltransferase,^{19–23} formylglycine generating enzyme²⁴ and sortase A²⁵ have also been investigated.

The bacterial transpeptidase, *Staphylococcus aureus* sortase A (SrtA) can be used for enzyme-mediated, site-specific incorporation of substrates onto suitably engineered target proteins.²⁶ The enzyme acts by recognising a short -LPETG- amino acid motif, cleaving the threonine-glycine bond and forming a thioacyl intermediate from a cysteine residue located in the active site.^{27,28} The enzyme then accepts an incoming nucleophilic N-terminal glycine to form a new amide bond. The incoming

glycine can be sourced from the cleaved peptide or from another peptide in solution containing the required N-terminal glycine, allowing for modification of the C-terminus of the substrate protein (Fig. 1).^{29–31} SrtA mediated bioconjugation has been used to install positron-emitting radionuclides into the variable region segment of a camelid heavy chain-only antibody (~15 kDa) to enable imaging of inflammation in mouse models.^{32–34} In our previous work, we used SrtA bioconjugation to install a copper-64 complex into a single-chain variable fragment antibody (~30 kDa) to allow imaging of activated platelets in a mouse model of thrombosis, but this work is the first time the approach has been used for attaching a copper chelator to EGFR-targeting Fab.²⁵

To label with zirconium-89 we prepared a squaramide ester derivative of desferrioxamine B, H₃DFOSq with a terminal *N*-glycine residue to enable it to act as a substrate for SrtA (Fig. 2). A DFOSq derivative was used for zirconium-89 labeling as the conjugates are easier to prepare, easier to radiolabel and often have superior solubility when compared to derivatives prepared with the commonly used desferrioxamine B isothiocyanate.³⁵ In addition, the [⁸⁹Zr]Zr^{IV} complexes that are formed are more resistant to ligand exchange.^{35,36} To develop the [⁶⁴Cu]Cu^{II}-based agents a derivative of the macrobicyclic sarcophagine (sar = 3,6,10,13,16,19-hexaazabicyclo-[6.6.6]icosane) cage amine ligand, MeCOSar (Fig. 2), with an N-




Fig. 2 Chemical structures of H₃DFOSqOEt, H₃L¹, MeCOSarNHS and L².



terminal glycine residue was used as radiolabeling can be achieved rapidly at room temperature to give high radiochemical yields and the complexes formed are stable *in vivo*.^{37–41} The new conjugates were evaluated in an EGFR positive A431 xenograft model and compared to conjugates of the full-length anti-EGFR IgG antibody, cetuximab, radio-labeled using the same metal chelators.

Results

Synthesis of metal chelators designed to be substrates for SrtA

The two ligands, H₃DFOSq and MeCOSar, were modified to act as substrates for SrtA by incorporation of a short oligoethylene

glycol (OEG) linker followed by a single N-terminal glycine residue to give H₃L¹ and L² (Fig. 2). The site-specific labeling of target proteins by SrtA-mediated bioconjugation results in the reformation of LPETG consensus sequence and this leads to the potential for the enzyme to initialise further reactions. The presence of a synthetic OEG linker adjacent to a glycine residue in the substrate produces a product where the new bioconjugate contains a LEPTG-OEG sequence, impeding further reactivity and improving isolated yields.

The synthesis of H₃DFOSq-OEG-Gly (H₃L¹) required a selective single protection of one of the two primary amines present in 4,7,10-trioxa-1,13-tridecanediamine with a *tert*-butoxycarbonyl group (*t*-Boc) to give mono-*t*-Boc protected OEG₃ diamine (**1**) (Fig. 3). Protection of the hydroxamic acid




Fig. 3 Reaction scheme for the synthesis of (a) compound **1** and (b) H₃L¹.






Fig. 4 A31 xenograft tumor-bearing NSG mice following administration with radiolabeled Fab528. (a) PET/CT MIPs (scale given in SUV) following administration with [⁸⁹Zr][ZrL¹]-Fab528. (b) Ex vivo biodistribution data following administration with [⁸⁹Zr][ZrL¹]-Fab528. (c) PET/CT MIPs following administration with [⁶⁴Cu][CuL²]-Fab528. (d) Ex vivo biodistribution data following administration with [⁶⁴Cu][CuL²]-Fab528. (e) SUV_{max} values and (f) tumor : background ratios for both tracers. All values are given as mean \pm SEM ($n = 3$).

functional groups in H₃DFOSq with iron(III) was followed by reaction of this iron(III) complex with the mono-protected diamine **1** to give [Fe(DFOSq-OEG-NH₂(*t*-Boc))] (**2**). Deprotection with trifluoroacetic acid followed by reaction with *t*-Boc protected *N*-hydroxy succinimidyl ester of glycine (*t*-BocGlyOSu) and a final deprotection resulted in [Fe(DFOSq-OEG-Gly)] ([FeL¹]). The iron(III) was removed with a large excess of disodium ethylenediamine tetraacetic acid (Na₂H₂EDTA) to give H₃L¹.

A suitably modified variant of MeCOSar with an OEG linker and a terminal NH₂-glycine residue, MeCOSarOEG-Gly (L², Fig. 2) was prepared from the *N*-hydroxysuccinimide-activated (*t*-Boc)₄₋₅MeCOSar-NHS ester as reported previously.⁴⁰

Assembly and expression of anti-EGFR 528 Fab fragments

The murine monoclonal antibody 528 binds to the ligand-binding domain III of the EGFR in a similar manner to cetuximab. Monovalent 528 antibody fragments retain high affinity ($K_D \sim 3$ nM) for the EGFR.⁴² To generate both LPETG-His₆ and LPETG-FLAG tagged Fab versions of 528 (Fab528), a DNA cassette was synthesised that facilitated the biosynthesis, assembly and secretion of tagged Fabs from a single mRNA following transfection of mammalian cells with the relevant expression vector. Preparations of each monovalent Fab were purified by a combination of affinity and gel filtration chromatography. Analysis of Fab528-LPETG-His₆ and Fab528-

LPETG-FLAG by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with samples prepared under non-reducing/reducing conditions revealed that the majority of both Fabs were in the form of LC:HC disulphide-linked dimers. The yield of recombinant Fabs was in the range of 8–10 mg per litre of transfected FreestyleTM-293 cells.

Purification of mixtures containing MeCOSar and its conjugates was difficult using conventional His₆-tag labeled proteins and immobilized metal affinity chromatography was complicated by low recovered yields. This is due to the sarcophagine chelator, which has extremely high affinities for first row transition metal ions, removing the Ni^{II} from the purification column. To circumvent this problem, the His₆ tags in the vectors encoding Fab528-LPETG-His₆, and SrtA-His₆ were replaced with FLAG tags. As a result, superior yields were obtained when Fab528-LPETG-FLAG and SrtA-FLAG were used in MeCOSar conjugation reactions.

Site-specific enzymatic incorporation of chelators into an anti-EGFR 528 fragment

The coupling of the H₃DFOSq derivative, H₃L¹, to Fab528-LPETG-His₆ was catalysed by SrtA-His₆ (60 µM) in the presence of Fab528-LPETG-His₆ (20 µM) and H₃L¹ (2 mM). Unreacted Fab528-LPETG-His₆, SrtA-His₆ and the resulting cleavage peptide were removed using affinity chromatography followed by centrifuge membrane filtration to remove unreacted H₃L¹. The Fab528-LPET-H₃L¹ conjugate (H₃L¹-Fab528, 75% yield) was

analysed by LC-ESIMS which confirmed a single addition of H₃DFOSq to the protein.

The coupling of the MeCOSar derivative, L², to Fab528-LPETG-FLAG was catalysed by SrtA-FLAG (60 µM), in the presence of Fab528-LPETG-FLAG (13 µM) and L² (2 mM). Purification by FLAG-affinity chromatography followed by centrifuge membrane filtration allowed isolation of Fab528-LPET-L² conjugate (L²-Fab528 90% yield) with the 1 : 1 ratio of protein to chelator confirmed by LC-ESIMS.

PET imaging of EGFR-positive tumors with an anti-EGFR 528 fragment radiolabeled with either zirconium-89 or copper-64

The H₃L¹-Fab528 conjugate was radiolabeled with zirconium-89 in HEPES buffer at pH 7.4 and purified using a size exclusion column to give [⁸⁹Zr][ZrL¹]-Fab528 with radiochemical yield of >60% and a radiochemical purity of ≥99% by radio-SEHPLC (0.7 MBq µg⁻¹) [⁸⁹Zr][ZrL¹]-Fab528 (2.2 MBq, ~3 µg) was administered to EGFR-positive A431 tumor-bearing NSG mice via tail vein injection (*n* = 3). PET/CT images were acquired at 1, 3 and 18 h post-administration. Inspection of the PET images (Fig. 4a) reveals excellent tumor uptake of [⁸⁹Zr][ZrL¹]-Fab528 even at 1 h post-administration.

Quantification of tumor uptake by calculating SUV_{max} (where SUV_{max} = maximum standardised uptake value, eqn (1), where *c*_{ROI} is the concentration of the highest pixel within the region of interest selected, ID is the injected activity and BW is body weight) resulted in a tumor SUV_{max} = 2.05 ± 0.05 at 1 h post-




Fig. 5 *In vivo* results following administration of [⁸⁹Zr][ZrDFOSq]-cetuximab in A431 xenograft tumor-bearing Balb/c nu/nu mice. (a) PET/CT MIP images (scale given in SUV). (b) SUV_{max} values (c) tumor : background ratios and (d) ex vivo biodistribution results. All values are given as mean ± SEM (*n* = 3).



administration that further increased to $SUV_{max} = 2.50 \pm 0.10$ at 3 h. There is significant retention of the $[^{89}\text{Zr}][\text{ZrL}^1]\text{Fab528}$ in the tumor out to 18 h post-administration (Fig. 4e). The high degree of kidney uptake and retention is expected for Fab fragments⁴³ but still permits PET images of high quality with good contrast between tumor to background (tumor : background ratio = 5.50 ± 0.30 and 7.00 ± 0.50 at 1 and 3 h respectively, where background is defined as an area of the mediastinum or gut, Fig. 4f).

$$SUV_{max} = \frac{c_{ROI}}{ID/BW} \quad (1)$$

The tumor uptake and biodistribution of $[^{89}\text{Zr}][\text{ZrL}^1]\text{Fab528}$ was also assessed at 2 and 48 h post-administration by ex vivo tissue analysis. Following intravenous injection of $[^{89}\text{Zr}][\text{ZrL}^1]\text{Fab528}$ (2.2 MBq, $\sim 3 \mu\text{g}$) the mice were euthanised at either 2 h or 48 h after administration and the amount of radioactivity in the tumor and major organs was quantified (Fig. 4b). The high tumor uptake of $[^{89}\text{Zr}][\text{ZrL}^1]\text{Fab528}$ was confirmed ($18 \pm 1\% \text{ IA g}^{-1}$ at 2 h post-administration) reducing to $4.2 \pm 0.3\% \text{ IA g}^{-1}$ at 48 h. The initial kidney uptake ($192 \pm 8\% \text{ IA g}^{-1}$ at 2 h) reduced to $109 \pm 6\% \text{ IA g}^{-1}$ at 48 h. Importantly, the degree of liver, spleen and bone uptake was relatively low ($< 6\% \text{ IA g}^{-1}$) at both 2 and 48 h.

The L²-Fab528 conjugate was radiolabeled with copper-64 in PBS (pH 7.4) at room temperature. The reaction was complete within 1 h to give $[^{64}\text{Cu}][\text{CuL}^2]\text{Fab528}$ with $> 95\%$ radiochemical purity by radio-SEHPLC and used without further purification

($0.18 \text{ MBq } \mu\text{g}^{-1}$). $[^{64}\text{Cu}][\text{CuL}^2]\text{Fab528}$ was administered to EGFR-positive A431 tumor-bearing NSG mice *via* tail vein injection (2.3 MBq, $\sim 13 \mu\text{g}$ each, $n = 3$). Mice underwent PET/CT imaging at 1, 3 and 18 h post-administration (Fig. 4c), with excellent tumor uptake evident at 1 h ($SUV_{max} = 3.4 \pm 0.9$) and retention at 18 h ($SUV_{max} = 2.0 \pm 0.2$). High kidney uptake and retention was also observed with $[^{64}\text{Cu}][\text{CuL}^2]\text{Fab528}$, while tumor : background ratios remained high (7.54 ± 2.16 and 8.11 ± 2.10 at 1 and 3 h, respectively). Mice were euthanised at 3 and 18 h post-injection, dissected and the activity in major organs was quantified (Fig. 4d). Uptake of $[^{64}\text{Cu}][\text{CuL}^2]\text{Fab528}$ was observed in the tumor at all timepoints, with the highest at 3 h ($5.76 \pm 0.25\% \text{ IA g}^{-1}$), decreasing to $4.12 \pm 0.11\% \text{ IA g}^{-1}$ by 18 h. Accumulation in off-target organs was also observed, with particularly high kidney uptake ($249 \pm 4\% \text{ IA g}^{-1}$ at 3 h) clearing to $201 \pm 5\% \text{ IA g}^{-1}$ at 18 h. Liver uptake evident in the images was confirmed ($9.2 \pm 0.3\% \text{ IA g}^{-1}$ decreasing to $7.6 \pm 0.1\% \text{ IA g}^{-1}$ at 3 & 18 h, respectively). Spleen uptake (maximum observed $6.0 \pm 0.5\% \text{ IA g}^{-1}$ at 18 h) and bone ($< 1\% \text{ IA g}^{-1}$ at all timepoints) remained low throughout the duration of the study.

PET imaging of EGFR positive tumors with cetuximab radiolabeled with either zirconium-89 or copper-64

The H₃DFOSq-cetuximab conjugate was prepared by treating the antibody with H₃DFOSqOEt³⁵ (Fig. 2) at room temperature overnight. Analysis of the purified conjugate by mass spectrometry revealed an average of ~ 3.9 chelators per antibody. Radiolabeling of H₃DFOSq-cetuximab with zirconium-89




Fig. 6 *In vivo* results following administration of $[^{64}\text{Cu}][\text{CuMeCOSar}]\text{-cetuximab}$ in A431 xenograft tumor-bearing NSG mice. (a) PET/CT MIP images (scale given in SUV). (b) SUV_{max} values (c) tumor : background ratios and (d) ex vivo biodistribution results. All values are given as mean \pm SEM ($n = 3$).



(HEPES buffer, pH 7) and purification by size-exclusion chromatography allowed isolation of $[^{89}\text{Zr}][\text{ZrDFOSq}]$ -cetuximab in a radiochemical yield of $\sim 64\%$ and $>95\%$ radiochemical purity with a specific activity of $0.64 \text{ MBq } \mu\text{g}^{-1}$. $[^{89}\text{Zr}][\text{ZrDFOSq}]$ -cetuximab (2.8 MBq, $\sim 5 \mu\text{g}$) was administered to EGFR-positive A431 tumor-bearing Balb/c nu/nu mice *via* tail vein injection ($n = 3$) and PET images were acquired at 24, 48 and 120 h post-administration. The PET images show excellent tumor uptake at 24 h post-administration ($\text{SUV}_{\text{max}} = 11.7 \pm 1.4$) (Fig. 5a and b) with an excellent tumor to background ratio of 19.6 ± 1.7 that increased to 24.4 ± 4.0 at 48 h post-administration (Fig. 5c). The high degree of tumor uptake was confirmed by quantification of radioactivity in the tumor and major organs at 24 and 120 h post-administration (Fig. 5d). The tumor uptake at 24 h post-administration ($51 \pm 2\% \text{ IA g}^{-1}$) was consistent with the high tumor uptake observed in the PET images. The uptake in the liver was $28 \pm 2\% \text{ IA g}^{-1}$ at 24 h post-administration and was similar at 120 h post-administration. The uptake in bone, $10.0 \pm 1.1\% \text{ IA g}^{-1}$ at 24 h post-administration increased to $21.1 \pm 1.5\% \text{ IA g}^{-1}$ at 120 h and this increase was evident in the epiphysis of the long bones in the PET images, likely due to the epiphyseal growth plates and the age of the mice.

The sarcophagine chelator, MeCOSar, was attached to cetuximab by treating the antibody with the *N*-hydroxysuccinimidyl ester MeCOSar-NHS^{39,40} (Fig. 2) for 30 min at 37°C (carbonate buffer, pH 9). Analysis of the MeCOSar-cetuximab conjugate by mass spectrometry revealed an average of ~ 3.6 MeCOSar chelators per antibody. Radiolabeling MeCOSar-cetuximab with copper-64 in ammonium acetate buffer, and purification with size-exclusion chromatography allowed isolation of $[^{64}\text{Cu}][\text{CuMeCOSar}]$ -cetuximab (40% radiochemical yield, $>95\%$ radiochemical purity by radio-iTLC, specific activity of $0.1 \text{ MBq } \mu\text{g}^{-1}$). $[^{64}\text{Cu}][\text{CuMeCOSar}]$ -cetuximab (2.1 MBq, $\sim 19 \mu\text{g}$) was administered to A431 tumor-bearing NSG mice *via* tail vein injection ($n = 3$). PET images were acquired at 1, 3 and 18 h post-administration ($n = 3$). The images show that whilst tumor uptake was evident at 1 h post-administration the best values of SUV_{max} (17.6 ± 0.8) and tumor : background ratios (14.4 ± 1.3) were at 24 h (Fig. 6a-c).

The high tumor uptake and retention was confirmed by an *ex vivo* biodistribution study (Fig. 6d) where tumor uptake at 3 h post-administration was $20 \pm 2\% \text{ IA g}^{-1}$ and was still $23 \pm 2\% \text{ IA g}^{-1}$ at 48 h post-administration. The liver uptake was $21.3 \pm 0.8\% \text{ IA g}^{-1}$ at 3 h, and this remained steady throughout the rest of the study. The uptake of the tracer in the spleen uptake increased from $23 \pm 1\% \text{ IA g}^{-1}$ at 3 h to $105 \pm 5\% \text{ IA g}^{-1}$ at 48 h. A significant amount of radioactivity was evident in bone in the images at later timepoints, (18, 24 and 48 h) and the *ex vivo* biodistribution study confirms this with the bone uptake at 3 h $4.2 \pm 0.2\% \text{ IA g}^{-1}$ increasing to $7.1 \pm 0.4\% \text{ IA g}^{-1}$ at 48 h post-administration.

Discussion

Two positron-emitting radionuclides with different radioactive half-lives, zirconium-89 ($t_{1/2} = 79 \text{ h}$, $\beta_{\text{mean}}^+ = 0.396 \text{ MeV}$) and

copper-64 ($t_{1/2} = 12.7 \text{ hours}$, $\beta_{\text{mean}}^+ = 0.278 \text{ MeV}$) were investigated. The relatively long radioactive half-life and amenable positron emission energy of zirconium-89 have seen the radio-nuclide emerge as the radionuclide of choice for PET imaging with full IgG antibodies.^{15,44,45} It was therefore of interest to directly compare the imaging characteristics of $[^{89}\text{Zr}][\text{ZrDFOSq}]$ -cetuximab with that of the smaller fragment, $[^{89}\text{Zr}][\text{ZrL}^1]$ -Fab528. A potential disadvantage of zirconium-89 is that β^+ -emission leads to the formation of ^{89m}Y , which itself decays rapidly through γ -emission (920 keV, $t_{1/2} = 15.7 \text{ s}$) to the stable ^{89}Y isotope. This relatively high-energy γ -emission adds to radiation exposure. From a practical consideration, ^{89}Zr needs more shielding for safe transport and handling than copper-64. The shorter radioactive half-life of copper-64 better suited for PET imaging with antibody fragments than zirconium-89, although imaging at least 24 hours after administration remains feasible.⁴⁶ A potential advantage of using copper-64 based imaging agents is that they can be used to predict dosimetry for the same conjugate labeled with copper-67, a potentially therapeutic β^- -emitting radionuclide ($t_{1/2} = 62 \text{ h}$).^{44,45,47-49}

Two variants of an anti-EGFR Fab528 containing a LPETG SrtA recognition sequence were developed, one with a His₆-tag and another with a FLAG tag to assist in purification.⁵⁰ A derivative of H₃DFOSq, suitably modified to act as a substrate for SrtA by the addition of a single N-terminal glycine residue separated from the chelator by an oligoethylene glycol spacer (H₃L¹), allowed the enzymatic incorporation of H₃L¹ into anti-EGFR Fab528 to give H₃L¹-Fab528 in good yields. This new construct was radiolabeled with zirconium-89 to give $[^{89}\text{Zr}][\text{ZrL}^1]$ -Fab528 in good radiochemical yield and purity. To enzymatically incorporate a copper-binding ligand into Fab528, a derivative of a sarcophagine ligand featuring a similar oligoethylene glycol-glycine, L², was used. The resulting conjugate could be radiolabeled with copper-64 at room temperature to give $[^{64}\text{Cu}][\text{CuL}^2]$ -Fab528.

Both $[^{89}\text{Zr}][\text{ZrL}^1]$ -Fab528 and $[^{64}\text{Cu}][\text{CuL}^2]$ -Fab528 were evaluated in an A431 xenograft mouse model. The A431 cell line has very high levels of EGFR expression. While this may not be representative of most clinical situations, the model is well-established and provides a good basis for the comparison of different tracers. It is interesting to note that previous imaging studies have shown that this high-expression cell line has only medium-level uptake of EGFR-binding antibodies *in vivo*, with other medium-level EGFR expression lines showing even greater uptake.⁵¹ In our study, both Fab528 agents displayed rapid clearance from the blood and significant uptake in the tumor at just 1 h post-administration of the tracer with $\text{SUV}_{\text{max}} = 2.05 \pm 0.05$ and 3.40 ± 0.94 and tumor : background ratios of 5.50 ± 0.30 and 7.54 ± 2.16 , respectively. There is a further increase in the tumor : background ratio at 3 hours post-administration to 7.00 ± 0.50 and 8.11 ± 2.10 . The majority of the background non-tumor bound radioactivity is in the kidneys. This is to be expected as small proteins such as Fab fragments generally undergo renal clearance, and is consistent with the renal uptake and retention of a ^{64}Cu -labeled cetuximab Fab fragment reported previously.⁵² F(ab)₂ fragments of



cetuximab have also been imaged with copper-64 although only 24 h imaging results were reported, with significant uptake in kidney and liver.^{10,53} In the case of [⁶⁴Cu][CuL²]-Fab528, there is also evidence of uptake in the liver and this is confirmed by the *ex vivo* biodistribution studies that reveal a slightly higher liver uptake ($9.19 \pm 0.30\%$ IA g⁻¹ at 3 h) than for the [⁸⁹Zr][ZrL¹]-Fab528 ($4.79 \pm 0.22\%$ IA g⁻¹ at 2 h). Liver uptake when using ⁶⁴Cu-based imaging agents is often attributed to 'free' Cu, but this is unlikely in the case of [⁶⁴Cu][CuL²]-Fab528. No 'free' copper was present on administration, and release of copper from MeCOSar *in vivo* has not been observed with other MeCOSar-based agents in mice,^{40,41} or humans⁵⁴ nor with [⁶⁴Cu][CuMeCOSar]-cetuximab, where liver uptake was antibody-mediated (Fig. 6). The differences in tumor and non-target uptake of the two Fab tracers highlights that modification of antibodies even with relatively low molecular weight metal complexes can alter biodistribution. The amount of antibody administered can also affect biodistribution and tumor uptake. In these studies picomole amounts of antibody conjugate were injected ([⁶⁴Cu][CuMeCOSar]-cetuximab 127 pmol, [⁸⁹Zr][ZrDFOSq]-cetuximab 33 pmol, [⁶⁴Cu][CuL²]-Fab528 260 pmol, [⁸⁹Zr][ZrL¹]-Fab528 60 pmol). It is likely that the number of receptors expressed in the tumour far outweighs the molecules of tracer administered, so the extent of tumour uptake is likely to reflect the clearance and permeability of the tracer rather than saturation of receptors or the number of receptors present.⁵⁵ Full IgG antibodies can also experience anomalous biodistribution in immune compromised mice due to Fc mediated interactions.⁵⁶

It is also notable that, in addition to the rapid tumor uptake, both agents display significant retention in the tumor, even at 18 h after administration (Fig. 4). It is possible that this antibody fragment may display sufficient affinity and residualization within the tumor to be used for radionuclide therapy. Many therapeutic radiopharmaceuticals have a mixture of renal and hepatobiliary clearance, with the former generally required to reduce circulation of unbound agent through bone marrow, which contributes to myelotoxicity, and the latter, generally slower excretion still maintaining bioavailability for tumor uptake. Sharing radiation dose between these two non-target organs, both of which are relatively radioresistant, also increases the therapeutic index.

The radiolabeled full IgG antibodies, [⁸⁹Zr]ZrDFOSq-cetuximab and [⁶⁴Cu]CuMeCOSar-cetuximab were radiolabeled under mild, room temperature conditions and no evidence of aggregation was observed by size exclusion chromatography. The conjugates showed excellent tumor uptake in the images, but at much later timepoints than the Fab528. This high tumor uptake evidenced by the SUV_{max} values from the images at 24 h (11.7 ± 1.4 and 17.6 ± 0.8 for ⁸⁹Zr and ⁶⁴Cu, respectively) was confirmed by the *ex vivo* measurements (⁸⁹Zr at 24 h = $51 \pm 2\%$ IA g⁻¹, ⁶⁴Cu at 48 h = $23.5 \pm 1.6\%$ IA g⁻¹). The tumor uptake of [⁶⁴Cu]CuMeCOSar-cetuximab is consistent with other ⁶⁴Cu cetuximab studies using DOTA.^{57,58} Potential advantages of using a MeCOSar chelator rather than DOTA include that MeCOSar-cetuximab can be radiolabeled at room temperature and that sarcophagine ligands form Cu^{II} complexes that are more stable *in vivo* than

complexes with DOTA (incubation of [⁶⁷Cu][Cu(sar)²⁺ in blood plasma for 174 h revealed $<2\%$ of the copper(II) dissociated from the complex).^{37,59} A previous study with a DFO-N-succinimide conjugated to cetuximab and radiolabeled with ⁸⁹Zr^{IV} exhibited much lower tumor uptake in A431 xenografts ($<8\%$ IA mL⁻¹) than what we observed using DFOSq-cetuximab (up to $51 \pm 2\%$ IA g⁻¹), although a different mouse strain was used.⁵¹

The lack of kidney uptake in the cetuximab images is unsurprising for these large proteins, which typically undergo hepatic rather than renal clearance. The radioactivity in the liver remained constant over the study period and similar levels were observed for both Zr ($27.5 \pm 2.3\%$ IA g⁻¹ at 24 h) and Cu ($21.3 \pm 0.8\%$ IA g⁻¹ at 3 h). Off-target uptake can compromise image quality if tumors are close to organs of high uptake (e.g. liver and kidney), and this has been previously demonstrated for liver metastases when using a Zr-labeled cetuximab in humans.⁶⁰ [⁶⁴Cu]Cu-cetuximab also exhibits high liver uptake in mouse models in our study and others.⁵⁷ Uptake in bone was evident with both conjugates (⁸⁹Zr at 24 h = $10 \pm 1\%$ IA g⁻¹, ⁶⁴Cu at 48 h = $7.1 \pm 0.4\%$ IA g⁻¹). It is often assumed that all bone uptake for zirconium labeled conjugates is due to 'free' ⁸⁹Zr^{IV} but the significant bone uptake following administration of the ⁶⁴Cu conjugate highlights that other factors can also contribute. Immune compromised mice can give anomalous biodistribution due to Fc-mediated interactions in innate immune effector cells within the bone marrow.⁵⁶ A limitation of this study is that different immunodeficient mouse strains were used for [⁸⁹Zr]ZrDFOSq-cetuximab (Balb/c nu/nu) and [⁶⁴Cu]CuMeCOSar (NSG) and this will produce different off-target distribution, including in the spleen.⁵⁶ The high spleen uptake of [⁶⁴Cu]CuMeCOSar-cetuximab in the NSG mice model is similar to what was reported in a previous study with ⁸⁹Zr-labeled cetuximab.⁵⁶

Although an extremely high tumor uptake ($51 \pm 2\%$ IA g⁻¹) was observed with ⁸⁹Zr-cetuximab at late timepoints, the requirement for a patient to return for imaging 24 h or more after administration adds complexities with respect to management of patients. With ⁶⁴Cu-cetuximab, although tumor uptake was observed at very early timepoints (SUV_{max} = 4.1 at 1 h), optimal tumor : background ratio was obtained at 24 h–48 h post administration. Both [⁶⁴Cu]CuMeCOSar-cetuximab and [⁸⁹Zr]ZrDFOSq-cetuximab displayed significant retention in the tumor. The high tumor uptake and retention of [⁶⁴Cu]CuMeCOSar-cetuximab suggests treatment with a ⁶⁷Cu variant is worth investigating as a potential agent for radionuclide therapy.

Methods

General

All reagents and solvents were obtained from standard commercial sources and unless otherwise stated were used as received. ¹H and ¹³C spectra were recorded with a Varian FT-NMR 400, Varian FT-NMR 500 or Varian FT-NMR 600 spectrometer (Varian, California USA). ¹H NMR spectra were acquired at 400, 500 or 600 MHz and ¹³C NMR spectra were acquired at 125.7 MHz. All NMR spectra were recorded at 25 °C



and all ^{13}C NMR was obtained as proton decoupled ^{13}C NMR, unless otherwise stated. The reported chemical shifts (in parts per million) are referenced relative to residual solvent signal. ESI-MS were recorded on an Agilent 6510 ESI-TOF LC/MS Mass Spectrometer (Agilent, California USA) or a Thermo Scientific Exactive Plus Orbitrap LC/MS (Thermo Fisher Scientific, Massachusetts, USA) and calibrated to internal references. Protein samples were analysed using an Agilent 6220 ESI-TOF LC/MS mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA). All data were acquired and reference mass corrected *via* a dual-spray electrospray ionisation (ESI) source. Acquisition was performed using the Agilent Mass Hunter Acquisition software version B.02.01 (B2116.30). Protein desalting and chromatographic separation was performed using an Agilent Poroshell C18 2.1×75 mm $5 \mu\text{m}$ column or Phenomenex Jupiter C5 $5 \mu\text{m}$ 300 \AA 2.1×50 mm column using 5% (v/v) acetonitrile ported to waste (0–5 min). Upon desalting of sample the flow was ported back into the ESI source for subsequent gradient elution with (5% (v/v) to 100% (v/v)) acetonitrile/0.1% formic acid over 8 min at 0.25 mL min^{-1} . Analysis was performed using Mass Hunter version B.06.00 with BioConfirm software. Protein concentrations were determined using a Merck Direct Detect® Spectrometer or a Thermo Fisher Scientific NanoDrop instrument (model NanoDrop One). All protein yields were calculated using the volume of solution obtained and the protein concentration of these solutions. ^{64}Cu was supplied as no carrier added [^{64}Cu]CuCl₂ in 0.02 M HCl by RAPID Laboratories, Medical Technology and Physics, Sir Charles Gairdner Hospital, Western Australia, or as no carrier added [^{64}Cu]CuCl₂ in 0.1 M HCl by Austin Health Molecular Imaging & Therapy, Victoria, Australia. ^{89}Zr was supplied as no carrier added [^{89}Zr]Zr(ox)₄ in 1 M oxalic acid by RAPID PET Laboratories, Radiometals Section, Medical Technology & Physics, Sir Charles Gairdner Hospital, Nedlands, WA, Australia, or by PerkinElmer Inc, BV Cyclotron VU, De Boelelaan 1081, HV Amsterdam, The Netherlands. For analysis of radioactive samples, size exclusion HPLC was performed on a Shimadzu SCL-10A VP/LC-10 AT VP system with a Shimadzu SPD-10A VP UV detector followed by a radiation detector (Ortec model 276 photomultiplier base with preamplifier, Ortec 925-SCINT ACE mate preamplifier, BIAS supply and SCA, Bicron 1M 11/2 photomultiplier tube) using a Phenomenex Yarra SEC-3000 3 μm 4.6×300 mm column (0.35 mL min^{-1} flow rate, 0.1 M phosphate buffer pH 6.8 mobile phase). Radio-iTLC were performed using a Raytest Rita-Star TLC scanner and silica gel impregnated glass fiber iTLC plates.

Chemical synthesis of H_3L^1 and L^2 are described in the ESI.†

$\text{H}_3\text{DFOSq-cetuximab}$

Cetuximab (100 μL , 1.8 mg, 12 nmol) was diluted in borate buffer (150 μL , 0.1 M, pH 9.0) and milli-Q H₂O (35 μL). $\text{H}_3\text{DFOSqOET}$ (12.3 μL , 10 mg mL^{-1} in DMSO, 0.18 μmol) was added and the reaction mixture allowed to stand at ambient temperature for 19 h. The mixture was then filtered using an Amicon 50 kDa MWCO centrifuge filter membrane. The membrane was washed ($2 \times 400 \mu\text{L}$ 4% DMSO in HEPES buffer

10 mM pH 7.4, then $1 \times 400 \mu\text{L}$ HEPES buffer 10 mM pH 7.4), and the resulting protein solution collected to give $\text{H}_3\text{DFOSq-cetuximab}$ (1.058 mg, 59%, ESI Fig. 2†).

MeCOSar-cetuximab

Cetuximab (30 μL , 0.4 mg) was diluted in carbonate buffer (30 μL , 0.1 M, pH 9.0). MeCOSarNHS (0.6 μL , 29 mg mL^{-1} in DMSO, 13 molar equivalents) was added and the reaction mixture allowed to stand at ambient temperature for 0.5 h. The mixture was then filtered using an Amicon 100 kDa MWCO centrifuge filter membrane. The membrane was washed ($2 \times 400 \mu\text{L}$ 10 mM ammonium acetate buffer pH 6.0), and the resulting protein solution collected to give MeCOSar-cetuximab (166 μg , 42%, ESI Fig. 3†).

Recombinant Fab528 fragments

A DNA template encoding a Fab fragment of the mouse IgG2a anti-EGFR monoclonal antibody, 528, codon-optimised for translation in human cells, was synthesised by Genscript (Piscataway, New Jersey) and sub-cloned into the mammalian expression vector, pCAGGS. The encoded Fab528 comprised the complete 528 light chain (LC), fused in-frame with a furin cleavage site, the foot-and-mouth disease virus (FMDV) 2A peptide, and the signal peptide, variable and CH1 constant regions of the 528 heavy chain (HC) (ESI Fig. 4†). A glycine-serine linker (Gly4Ser)2 was introduced between the C-terminus of the CH1 domain and a SrtA recognition sequence (LPETGG), followed by an alanine spacer (Ala3) and either a His6 (HHHHHH) or FLAG (DYKDDDDK) affinity tag. Mammalian expression vectors encoding Fab528-LPETG-His6 and Fab528-LPETG-FLAG were transiently transfected into suspension-adapted cultures of FreestyleTM-293 cells (Thermo Fisher Scientific) using linear polyethyleneimine (PEI, Polysciences, Inc., Warrington, PA) and secreted Fabs purified by immobilized metal ion affinity chromatography (IMAC; Fab528-LPETG-His6) or M2 monoclonal antibody anti-FLAG immunoaffinity chromatography (Fab528-LPETG-FLAG) followed by gel filtration.⁶¹

Recombinant SrtA-His₆ and FLAG-SrtA

The expression and purification of His-tagged, recombinant SrtA (SrtA-His₆) from *E. coli* has been described previously.^{40,42} To enable the expression and purification of a FLAG-tagged version of SrtA, the coding region of SrtA was excised from the SrtA-His₆ vector and subcloned in-frame into a PET28a vector modified to include an N-terminal FLAG tag. Expression of SrtA-FLAG was induced using standard protocols and purified by M2 anti-Flag immunoaffinity chromatography.

$\text{H}_3\text{L}^1\text{-Fab528}$

Fab528-LPETG-His₆ (300 μg , 5.99 nmol) was diluted in SrtA reaction buffer (137 μL , for a final concentration of 50 mM tris, 150 mM NaCl, 10 mM CaCl₂, pH 7.5), followed by the addition of H_3L^1 (50 mM in DMSO, 11.5 μL , 575 nmol). SrtA-His₆ (327 μg , 17.3 nmol) was then added. The reaction mixture was incubated for 18.5 h at 37 °C with gentle shaking (250 rpm), then



quenched by cooling to 4 °C. The mixture was then incubated with Qiagen NiNTA resin (75 µL) in PBS (50 mM, 0.7 mL) at 4 °C with shaking for 1 h. The supernatant was collected and filtered on an Amicon 10 kDa MWCO centrifuge filter, and washed on the filter (2× 400 µL HEPES buffer, 10 mM, pH 7.4) to give H₃L¹-Fab528 (224 µg, 75%, ESI Fig. 5†).

L²-Fab528

Fab528LPETG-FLAG (300 µg) was diluted in SrtA reaction buffer (144 µL, for a final concentration of 50 mM tris, 150 mM NaCl, 10 mM CaCl₂, pH 7.5), followed by the addition of L² (50 mM in DMSO, 18 µL). SrtA-FLAG (500 µg) was then added. The reaction mixture was incubated overnight at 37 °C with gentle shaking (500 rpm), then quenched by cooling to 4 °C. The mixture was then incubated with anti-DYKDDDDK affinity resin in binding buffer (PBS pH 7.4, 1 mL) at 4 °C with shaking for 3 h. The supernatant was collected and filtered on an Amicon 10 kDa MWCO centrifuge filter and washed on the filter (2× 400 µL ammonium acetate buffer, 100 mM, pH 6) to give L²-Fab528 (269 µg, 90%, ESI Fig. 6†).

[⁸⁹Zr]ZrDFOSq-cetuximab

A solution of ⁸⁹Zr in 1 M oxalic acid (140 µL, 100 MBq) was diluted with milli-Q H₂O (140 µL), then neutralised through sequential addition of small aliquots of Na₂CO₃ (total 113 µL, 1 M) to pH 7. HEPES buffer (130 µL, 1 M, pH 7.4) was then added. H₃DFOSq-cetuximab (9.5 µL, 100 µg) was added to the buffered ⁸⁹Zr solution and left to stand at ambient temperature for 75 min. The reaction mixture was then purified using a PD-10 column conditioned with PBS and 0.5% sodium gentisate. Four 500 µL fractions were collected, and the fraction with the highest activity (28.9 MBq) selected. Radiochemical purity was confirmed by radio-SEHPLC, the remaining fraction was diluted further (600 µL of PBS/gentisate) and six doses (2.9 MBq in 120 µL each) were drawn up into 0.3 mL insulin syringes. Each dose was administered *via* tail vein injection into A431 xenograft tumor-bearing nude mice.

[⁸⁹Zr]ZrL¹-Fab528

A solution of ⁸⁹Zr^{IV} in 1 M oxalic acid (141 µL, 160 MBq) was diluted with milli-Q H₂O (141 µL), then neutralised through sequential addition of small aliquots of Na₂CO₃ (total 118 µL, 1 M) to pH 7. HEPES buffer (200 µL, 1 M, pH 7.4) was then added. H₃L¹-Fab528 (50 µg) was added to a portion of the buffered ⁸⁹Zr^{IV} solution (125 µL, 20 MBq) and left to stand at ambient temperature for 45 min. Radio-SEHPLC indicated approximately 70% labeling, and so a further portion of ⁸⁹Zr^{IV} (375 µL, 60 MBq) was added with a further 20 µg of H₃L¹-Fab528. After a further 40 min, the reaction mixture was purified using a PD-10 column conditioned with PBS and 0.5% sodium gentisate. Four 500 µL fractions were collected, and the fraction with the highest activity (27.2 MBq) selected. Radiochemical purity was confirmed by radio-SEHPLC, the remaining fraction was diluted further (1.02 mL of PBS/gentisate) and six doses (2.2 MBq, 3 µg 150 µL each) were drawn up into 0.3 mL insulin syringes. Each

dose was administered *via* tail vein injection into A431 xenograft tumor-bearing NSG mice.

[⁶⁴Cu]CuMeCOSar-cetuximab

A solution of [⁶⁴Cu]CuCl₂ in 0.1 M HCl (24 µL, 40 MBq) was buffered to pH 6 with ammonium acetate (48 µL, 0.1 M). MeCOSar-cetuximab (92 µL, 152 µg) was added and the mixture left to stand at ambient temperature for 30 min. The reaction mixture was then purified using a PD-10 column conditioned with PBS. Radiochemical purity was confirmed by radio-iTLC, and the sample was diluted further with PBS and six doses (2.1 MBq, 19 µg, 175 µL each) were drawn up into 0.3 mL insulin syringes. Each dose was administered *via* tail vein injection into A431 xenograft tumor-bearing NSG mice.

[⁶⁴Cu]CuL²-Fab528

A solution of [⁶⁴Cu]CuCl₂ in 0.02 M HCl (17 µL, 33 MBq) was buffered to pH 7 with PBS (100 µL). L²-Fab528 (148 µL, 188 µg) was added and the mixture left to stand at ambient temperature for 1 h. Radiochemical purity was confirmed by radio-SEHPLC and the reaction mixture was used without further purification. The mixture was further diluted with PBS and six doses of [⁶⁴Cu]CuL²-Fab528 (2.3 MBq, 13 µg, 200 µL each) were drawn up into 0.3 mL insulin syringes. Each dose was administered *via* tail vein injection into A431 xenograft tumor-bearing NSG mice.

Mice imaging

All animal experiments were performed with the approval of the Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee and in accordance with the Australian code for the care and use of animals for scientific purposes, 8th Edition, 2013. Balb/c nude and NSG mice were sourced from Animal BioResources, (Moss Vale, New South Wales). 3 × 10⁶ A431 cells (American Type Culture Collection) were implanted subcutaneously onto the right flank of the mice and once tumors were well established, the animals were used for imaging and biodistribution studies. For PET-CT imaging, animals were anaesthetised with 2.5% isoflurane and placed in the imaging chamber of a PerkinElmer/Sofie Biosciences small animal G8 PET/CT. A CT scan was performed followed by a 10 min PET acquisition. Images were acquired using the G8 acquisition engine software and reconstructed using a 3D ML-EM algorithm. Quantification was performed using VivoQuant software, Version 3.0 (inviCRO Imaging Services and Software). After imaging the final time point mice were euthanized and tissues excised, weighed and counted using a Capintec (Captus 4000e) gamma counter. Separate cohorts of mice were harvested for earlier biodistribution time points.

Conclusions

The effective use of EGFR targeting therapies relies on personalised medicine where diagnostic molecular imaging can provide relatively quick selection of suitable patients as well as rapid assessment of clinical responses. The antibody fragments used in this study were genetically modified to incorporate



a SrtA recognition sequence to allow enzyme mediated site selective incorporation of either copper-64 or zirconium-89. For each radionuclide the respective chelators were also modified by the inclusion of a N-terminal glycine, so the chelator is also able to act as substrate for SrtA. The use of SrtA to attach the chelator has the added benefit of potentially simplifying regulatory approval for clinical use of these tracers, as the mixtures obtained with non-specific attachment methods can be challenging to reproduce and characterise. The Fab528 conjugates are potentially easier to manufacture reproducibly in terms of chelator-to-antibody ratio.

Both $[^{64}\text{Cu}][\text{CuL}^2]$ -Fab528 and $[^{89}\text{Zr}][\text{ZrL}^1]$ -Fab528 were able to give high quality PET images with high tumor uptake when imaging 3 hours post-injection in A431 EGFR-positive tumors. The shorter time between injection and imaging represents a potential advantage of the smaller Fab528 agents when compared to the radiolabeled full antibody agents that require several days between injection and imaging. The high kidney uptake and retention using the Fab528 conjugates may be an acceptable trade-off for the liver uptake in the full IgG conjugates in terms of radiation dose, but this remains to be confirmed. The shorter radioactive half-life of copper-64 is perhaps better suited to imaging within this relatively short time frame than zirconium-89. Another potential advantage of using copper-64 based imaging agents is that they can be used to predict dosimetry for the same conjugate labeled with copper-67, a potentially therapeutic β^- -emitting radionuclide ($t_{1/2} = 62$ h).^{49,62} The ability to obtain suitable images in 1–3 hours post injection suggest diagnostic imaging with ^{68}Ga , a positron-emitting radionuclide that is available from a generator and has a radioactive half-life of 68 minutes, could be feasible. The DFOSq chelator can also be used to coordinate to $^{68}\text{Ga}^{III}$.⁶³ The major advantage of the Fab528 conjugates presented is that high-quality PET images can be acquired three hours after administration and this could translate to same day imaging in humans improving the feasibility of diagnostic EGFR PET imaging.

Author contributions

S. E. Rudd conducted the chemical synthesis, enzyme-mediated bioconjugations, chemical characterisations and radiolabelling and wrote the initial manuscript draft. J. K. Van Zuylen conducted the mouse experiments and PET data analysis. A. Raicevic and L. A. Pearce expressed the 528 protein and Sortase enzyme. C. Cullinane, C. C. Williams, T. E. Adams, R. J. Hicks and P. S. Donnelly conceptualized the research, directed the project and finalized the manuscript. All authors contributed discussions and manuscript editing.

Conflicts of interest

Stacey E. Rudd and Paul S. Donnelly are inventors on intellectual property relating to the use of DFOSq that have been licenced from the University of Melbourne to Telix Pharmaceuticals. Paul S. Donnelly is an inventor of intellectual property relating to this area of research that has been licensed from the

University of Melbourne to Clarity Pharmaceuticals. Paul S. Donnelly serves on the Scientific Advisory board and has a financial interest in Clarity Pharmaceuticals. Rodney J. Hicks has shares in Telix Pharmaceuticals.

Acknowledgements

Funding from the Australian Research Council and the National Health and Medical Research Council. The G8 PET/CT scanner was purchased with the support of a grant from the Australian Cancer Research Foundation. We thank the Mass Spectrometry and Proteomics Facility at Bio21 Institute, University of Melbourne. We also thank Professor Roger I. Price, Dr Ali Asad and Thien Dinh for provision of $^{89}\text{Zr}/^{64}\text{Cu}$. Susan Jackson and Rachael Walker for expert technical assistance with mouse models, Stewart Nuttall for pET28a-FLAG vector, Stephan Eckert and Laura Castelli for help with vector cloning, the Fermentation Team (National Biologics Facility) for scale-up cell culture and transfections, Jo Caine for help with protein purification, and Dr Mark Richardson for assistance with figures. The National Biologics Facility is supported by Therapeutic Innovation Australia through the National Collaborative Research Infrastructure Strategy.

References

- Y. Yarden and M. X. Sliwkowski, *Nat. Rev. Mol. Cell Biol.*, 2001, **2**, 127–137.
- R. Pirker, *Curr. Opin. Oncol.*, 2015, **27**, 87–93.
- R. S. Herbst, M. W. Redman, E. S. Kim, T. J. Semrad, L. Bazhenova, G. Masters, K. Oettel, P. Guaglianone, C. Reynolds, A. Karnad, S. M. Arnold, M. Varella-Garcia, J. Moon, P. C. Mack, C. D. Blanke, F. R. Hirsch, K. Kelly and D. R. Gandara, *Lancet Oncol.*, 2018, **19**, 101–114.
- T. Mizukami, N. Izawa, T. E. Nakajima and Y. Sunakawa, *Drugs*, 2019, **79**, 633–645.
- F. Penault-Llorca, A. Cayre, L. Arnould, F. Bibeau, M. Bralet, P. Rochaix, J. Savary and J. Sabourin, *Oncol. Rep.*, 2006, **16**, 1173–1179.
- M. Francoual, M. C. Etienne-Grimaldi, J. L. Formento, D. Benchimol, A. Bourgeon, M. Chazal, C. Letoublon, T. André, N. Gilly, J. R. Delpero, P. Lasser, J. P. Spano and G. Milano, *Annals of Oncology*, 2006, **17**, 962–967.
- P. M. R. Pereira, L. Abma, K. E. Henry and J. S. Lewis, *Cancer Lett.*, 2018, **419**, 139–151.
- D. Zeng, Y. Guo, A. G. White, Z. Cai, J. Modi, R. Ferdani and C. J. Anderson, *Mol. Pharm.*, 2014, **11**, 3980–3987.
- S. M. Larson, J. A. Carrasquillo, K. A. Krohn, J. P. Brown, R. W. McGuffin, J. M. Ferens, M. M. Graham, L. D. Hill, P. L. Beaumier and K. E. Hellström, *J. Clin. Invest.*, 1983, **72**, 2101–2114.
- N. S. Turker, P. Heidari, R. Kucherlapati, M. Kucherlapati and U. Mahmood, *Theranostics*, 2014, **4**, 893–903.
- T. Olafsen and A. M. Wu, *Semin. Nucl. Med.*, 2010, **40**, 167–181.
- J. D. Sato, T. Kawamoto, A. D. Le, J. Mendelsohn, J. Polikoff and G. H. Sato, *Mol. Biol. Med.*, 1983, **1**, 511–529.

13 K. Lang and J. W. Chin, *Chem. Rev.*, 2014, **114**, 4764–4806.

14 J. N. Tinianow, H. S. Gill, A. Ogasawara, J. E. Flores, A. N. Vanderbilt, E. Luis, R. Vandlen, M. Darwish, J. R. Junutula, S.-P. Williams and J. Marik, *Nucl. Med. Biol.*, 2010, **37**, 289–297.

15 M. A. Deri, B. M. Zeglis, L. C. Francesconi and J. S. Lewis, *Nucl. Med. Biol.*, 2013, **40**, 3–14.

16 P. Strop, S.-H. Liu, M. Dorywalska, K. Delaria, R. G. Dushin, T.-T. Tran, W.-H. Ho, S. Farias, M. G. Casas, Y. Abdiche, D. Zhou, R. Chandrasekaran, C. Samain, C. Loo, A. Rossi, M. Rickert, S. Krimm, T. Wong, S. M. Chin, J. Yu, J. Dilley, J. Chaparro-Riggers, G. F. Filzen, C. J. O'Donnell, F. Wang, J. S. Myers, J. Pons, D. L. Shelton and A. Rajpal, *Chem. Biol.*, 2013, **20**, 161–167.

17 P. Dennler, A. Chiotellis, E. Fischer, D. Brégeon, C. Belmant, L. Gauthier, F. Lhospice, F. Romagne and R. Schibli, *Bioconjugate Chem.*, 2014, **25**, 569–578.

18 F. Lhospice, D. Brégeon, C. Belmant, P. Dennler, A. Chiotellis, E. Fischer, L. Gauthier, A. Boëdec, H. Rispaud, S. Savard-Chambard, A. Represa, N. Schneider, C. Paturel, M. Sapet, C. Delcambre, S. Ingoue, N. Viaud, C. Bonnafous, R. Schibli and F. Romagné, *Mol. Pharm.*, 2015, **12**, 1863–1871.

19 B. M. Zeglis, C. B. Davis, R. Aggeler, H. C. Kang, A. Chen, B. J. Agnew and J. S. Lewis, *Bioconjugate Chem.*, 2013, **24**, 1057–1067.

20 B. M. Zeglis, C. B. Davis, D. Abdel-Atti, S. D. Carlin, A. Chen, R. Aggeler, B. J. Agnew and J. S. Lewis, *Bioconjugate Chem.*, 2014, **25**, 2123–2128.

21 P. Adumeau, D. Vivier, S. K. Sharma, J. Wang, T. Zhang, A. Chen, B. J. Agnew and B. M. Zeglis, *Mol. Pharm.*, 2018, **15**, 892–898.

22 B. Ramakrishnan and P. K. Qasba, *J. Biol. Chem.*, 2002, **277**, 20833–20839.

23 B. Ramakrishnan, E. Boeggeman, M. Manzoni, Z. Zhu, K. Loomis, A. Puri, D. S. Dimitrov and P. K. Qasba, *Bioconjugate Chem.*, 2009, **20**, 1383–1389.

24 P. Wu, W. Shui, B. L. Carlson, N. Hu, D. Rabuka, J. Lee and C. R. Bertozzi, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 3000–3005.

25 B. M. Paterson, K. Alt, C. M. Jeffery, R. I. Price, S. Jagdale, S. Rigby, C. C. Williams, K. Peter, C. E. Hagemeyer and P. S. Donnelly, *Angew. Chem., Int. Ed.*, 2014, **53**, 6115–6119.

26 S. K. Mazmanian, G. Liu, H. Ton-That and O. Schneewind, *Science*, 1999, **285**, 760.

27 H. Ton-That, G. Liu, S. K. Mazmanian, K. F. Faull and O. Schneewind, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 12424.

28 Y. Zong, T. W. Bice, H. Ton-That, O. Schneewind and S. V. L. Narayana, *J. Biol. Chem.*, 2004, **279**, 31383–31389.

29 M. W. Popp, J. M. Antos, G. M. Grotenbreg, E. Spooner and H. L. Ploegh, *Nat. Chem. Biol.*, 2007, **3**, 707.

30 M. W.-L. Popp and H. L. Ploegh, *Angew. Chem., Int. Ed.*, 2011, **50**, 5024–5032.

31 H. Mao, S. A. Hart, A. Schink and B. A. Pollok, *J. Am. Chem. Soc.*, 2004, **126**, 2670–2671.

32 M. Rashidian, E. J. Keliher, A. M. Bilate, J. N. Duarte, G. R. Wojtkiewicz, J. T. Jacobsen, J. Cagnolini, L. K. Swee, G. D. Victora, R. Weissleder and H. L. Ploegh, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 6146–6151.

33 M. Rashidian, L. Wang, J. G. Edens, J. T. Jacobsen, I. Hossain, Q. Wang, G. D. Victora, N. Vasdev, H. Ploegh and S. H. Liang, *Angew. Chem., Int. Ed.*, 2016, **55**, 528–533.

34 M. Rashidian, J. R. Ingram, M. Dougan, A. Dongre, K. A. Whang, C. LeGall, J. J. Cagnolini, B. Bierie, M. Gostissa, J. Gorman, G. M. Grotenbreg, A. Bhan, R. A. Weinberg and H. L. Ploegh, *J. Exp. Med.*, 2017, **214**, 2243–2255.

35 S. E. Rudd, P. Roselt, C. Cullinane, R. J. Hicks and P. S. Donnelly, *Chem. Commun.*, 2016, **52**, 11889–11892.

36 C. B. Jacobsen, R. Raave, M. O. Pedersen, P. Adumeau, M. Moreau, I. E. Valverde, I. Bjoernsdottir, J. B. Kristensen, M. F. Grove, K. Raun, J. McGuire, V. Goncalves, S. Heskamp, F. Denat and M. Gustafsson, *Nucl. Med. Biol.*, 2020, **82–83**, 49–56.

37 N. M. Di Bartolo, A. M. Sargeson, T. M. Donlevy and S. V. Smith, *J. Chem. Soc., Dalton Trans.*, 2001, 2303–2309.

38 S. D. Voss, S. V. Smith, N. DiBartolo, L. J. McIntosh, E. M. Cyr, A. A. Bonab, J. L. J. Dearling, E. A. Carter, A. J. Fischman, S. T. Treves, S. D. Gillies, A. M. Sargeson, J. S. Huston and A. B. Packard, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 17489–17493.

39 K. Alt, B. M. Paterson, K. Ardipradja, C. Schieber, G. Buncic, B. Lim, S. S. Poniger, B. Jakoby, X. Wang, G. J. O'Keefe, H. J. Tochon-Danguy, A. M. Scott, U. Ackermann, K. Peter, P. S. Donnelly and C. E. Hagemeyer, *Mol. Pharm.*, 2014, **11**, 2855–2863.

40 B. M. Paterson, P. Roselt, D. Denoyer, C. Cullinane, D. Binns, W. Noonan, C. M. Jeffery, R. I. Price, J. M. White, R. J. Hicks and P. S. Donnelly, *Dalton Trans.*, 2014, **43**, 1386–1396.

41 B. M. Paterson, G. Buncic, L. E. McInnes, P. Roselt, C. Cullinane, D. S. Binns, C. M. Jeffery, R. I. Price, R. J. Hicks and P. S. Donnelly, *Dalton Trans.*, 2015, **44**, 4901–4909.

42 M. P. Madej, G. Coia, C. C. Williams, J. M. Caine, L. A. Pearce, R. Attwood, N. A. Bartone, O. Dolezal, R. M. Nisbet, S. D. Nuttall and T. E. Adams, *Biotechnol. Bioeng.*, 2012, **109**, 1461–1470.

43 T. M. Behr, D. M. Goldenberg and W. Becker, *Eur. J. Nucl. Med.*, 1998, **25**, 201–212.

44 E. Boros and A. B. Packard, *Chem. Rev.*, 2019, **119**, 870–901.

45 L. E. McInnes, S. E. Rudd and P. S. Donnelly, *Coord. Chem. Rev.*, 2017, **352**, 499–516.

46 C. J. Anderson, J. M. Connell, S. W. Schwarz, P. A. Rocque, L. W. Guo, G. W. Philpott, K. R. Zinn, C. F. Meares and M. J. Welch, *J. Nucl. Med.*, 1992, **33**, 1685–1690.

47 S. J. DeNardo, G. L. DeNardo, D. L. Kukis, S. Shen, L. A. Kroger, D. A. DeNardo, D. S. Goldstein, G. R. Mirick, Q. Salako, L. F. Mausner, S. C. Srivastava and C. F. Meares, *J. Nucl. Med.*, 1999, **40**, 302–310.

48 P. J. Blower, *J. Chem. Soc., Dalton Trans.*, 2015, **44**, 4819–4844.

49 C. Cullinane, C. M. Jeffery, P. D. Roselt, E. M. van Dam, S. Jackson, K. Kuan, P. Jackson, D. Binns, J. van Zuylenkom, M. J. Harris, R. J. Hicks and P. S. Donnelly, *J. Nucl. Med.*, 2020, **61**, 1800–1805.



50 C. P. Guimaraes, M. D. Witte, C. S. Theile, G. Bozkurt, L. Kundrat, A. E. M. Blom and H. L. Ploegh, *Nat. Protoc.*, 2013, **8**, 1787–1799.

51 H. J. Aerts, L. Dubois, L. Perk, P. Vermaelen, G. A. van Dongen, B. G. Wouters and P. Lambin, *J. Nucl. Med.*, 2009, **50**, 123–131.

52 R. Chakravarty, S. Goel, H. F. Valdovinos, R. Hernandez, H. Hong, R. J. Nickles and W. Cai, *Bioconjugate Chem.*, 2014, **25**, 2197–2204.

53 L. K. van Dijk, C.-B. Yim, G. M. Franssen, J. H. A. M. Kaanders, J. Rajander, O. Solin, T. J. Groenroos, O. C. Boerman and J. Bussink, *Contrast Media Mol. Imaging*, 2016, **11**, 65–70.

54 R. J. Hicks, P. Jackson, G. Kong, R. E. Ware, M. S. Hofman, D. A. Pattison, T. A. Akhurst, E. Drummond, P. Roselt, J. Callahan, R. Price, C. M. Jeffery, E. Hong, W. Noonan, A. Herschtal, L. J. Hicks, A. Hedd, M. Harris, B. M. Paterson and P. S. Donnelly, *J. Nucl. Med.*, 2019, **60**, 777–785.

55 R. M. Reilly, R. Kiarash, J. Sandhu, Y. W. Lee, R. G. Cameron, A. Hendl, K. Vallis and J. Gariépy, *J. Nucl. Med.*, 2000, **41**, 903.

56 S. K. Sharma, A. Chow, S. Monette, D. Vivier, J. Pourat, K. J. Edwards, T. R. Dilling, D. Abdel-Atti, B. M. Zeglis, J. T. Poirier and J. S. Lewis, *Cancer Res.*, 2018, **78**, 1820–1832.

57 W. Cai, K. Chen, L. He, Q. Cao, A. Koong and X. Chen, *Eur. J. Nucl. Med. Mol. Imaging*, 2007, **34**, 850–858.

58 L. A. M. Wen Ping Li, D. A. Capretto, C. D. Sherman and a. C. J. Anderson, *Cancer Biother. Radiopharm.*, 2008, **23**, 158–171.

59 M. S. Cooper, M. T. Ma, K. Sunassee, K. P. Shaw, J. D. Williams, R. L. Paul, P. S. Donnelly and P. J. Blower, *Bioconjugate Chem.*, 2012, **23**, 1029–1039.

60 C. W. Menke, E. C. Gootjes, M. C. Huisman, N. C. T. v. Grieken, D. J. Vugts, C. Roth, E. R. Mulder, R. C. Schuit, R. Boellaard, O. S. Hoekstra, G. A. M. S. v. Dongen and H. M. W. Verheul, *J. Clin. Oncol.*, 2014, **32**, 11102.

61 T. C. Elleman, T. Domagala, N. M. McKern, M. Nerrie, B. Lönnqvist, T. E. Adams, J. Lewis, G. O. Lovrecz, P. A. Hoyne, K. M. Richards, G. J. Howlett, J. Rothacker, R. N. Jorissen, M. Lou, T. P. J. Garrett, A. W. Burgess, E. C. Nice and C. W. Ward, *Biochemistry*, 2001, **40**, 8930–8939.

62 O. Keinänen, K. Fung, J. M. Brennan, N. Zia, M. Harris, E. van Dam, C. Biggin, A. Hedd, J. Stoner, P. S. Donnelly, J. S. Lewis and B. M. Zeglis, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 28316–28327.

63 A. Noor, J. K. Van Zuylenkom, S. E. Rudd, K. Waldeck, P. D. Roselt, M. B. Haskali, M. P. Wheatcroft, E. Yan, R. J. Hicks, C. Cullinane and P. S. Donnelly, *J. Med. Biochem.*, 2020, **63**, 9258–9270.

